bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 846: Associations of dietary and lifestyle oxidative balance scores with all-cancer, all-CVD, and all-cause mortality risk among older women: The Iowa Women's Health Study
Authors: Mao Ziling , Prizment Anna E. , Lazovich DeAnn , Bostick Boberd M. 
Published: July 2021

Abstract
Background: Substantial basic science evidence suggests that oxidative stress may play a role in aging-related health outcomes, including cancer and cardiovascular diseases (CVD), and oxidative stress markers were linked with all-cancer, all-CVD, and all-cause mortality in epidemiologic studies. However, the associations of many individual dietary and lifestyle anti-/pro-oxidant exposures with mortality are inconsistent. Oxidative balance scores (OBS) that incorporated multiple dietary and lifestyle factors were previously developed and reported to reflect the collective oxidative effects of multiple exposures.
Methods: We investigated associations of 11-component dietary and 4-component (physical activity, adiposity, alcohol, and smoking) lifestyle OBS (higher scores were considered more anti-oxidative) with all-cancer, all-CVD, and all-cause mortality among women 55 - 69 years of age at baseline in the prospective Iowa Women's Health Study (1986 - 2012). We assessed OBS-mortality associations using multivariable Cox proportional hazards regression.
Results: Of the 34,137 cancer-free women included in the analytic cohort, 18,058 died (4,521 from cancer, and 6,825 from CVD) during a mean/median 22.0/26.1 person-years of follow up. Among participants in the highest relative to the lowest lifestyle OBS quintiles, the adjusted hazards ratios and their 95% confidence intervals for all-cancer, all-CVD, and all-cause mortality were 0.47 (0.43, 0.52), 0.54 (0.54, 0.58), and 0.50 (0.48, 0.53) (all Ptrend &lt; 0.001), respectively. The associations of the dietary OBS with mortality were close to null.
Conclusion: Our findings, combined with results from previous studies, suggest that a predominance of antioxidant over pro-oxidant lifestyle exposures may be associated with lower all-cancer, all-CVD, and all-cause mortality risk.
Citation Format: Ziling Mao, Anna E. Prizment, DeAnn Lazovich, Boberd M. Bostick. Associations of dietary and lifestyle oxidative balance scores with all-cancer, all-CVD, and all-cause mortality risk among older women: The Iowa Women's Health Study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 846.
Abstract 850: Multivitamin use and risk of overall and site-specific cancer in the National Institutes of Health - AARP Diet and Health Study
Authors: Lim Jungeun , Weinstein Stephanie J. , Liao Linda M. , Huang Jiaqi , Albanes Demetrius 
Published: July 2021

Abstract
Although multivitamins are among the most commonly used supplements in the U.S., their effectiveness in preventing cancer and other chronic diseases is unclear. To help address this uncertainty, we prospectively investigated the association between multivitamin use and risk of overall and site-specific cancer in 489,640 participants enrolled in the National Institutes of Health (NIH) - AARP Diet and Health Study. We defined site-specific cancers using the Surveillance Epidemiology and End Results (SEER) incidence and the International Classification of Diseases for Oncology coding (3rd ed.). Multivitamin use was assessed by questionnaire at baseline and categorized as never, &lt;3 times per week, 3-6 times per week, daily, and &gt;1 per day. Cox proportional hazards regression models of multivitamin use estimated hazard ratios (HRs) and 95% confidence intervals (CIs) that adjusted for multiple potential confounders including gender, age, body mass index, smoking status, and Healthy Eating Index-2015 (HEI-2015) score. We observed no association between increasing multivitamin use and overall cancer risk (HRs 1.0 (reference, never use) 0.94, 0.96, 1.01, 1.00; trend P-value=0.42). Multivitamin use was, however, inversely associated with colon cancer risk: HR=0.79, 95% CI=0.70-0.89 (trend P-value&lt;0.0001) among participants taking &gt;1 multivitamin daily compared with never users, a finding that was identical in men and women (HR=0.79, 95% CI=0.68-0.92 and HR=0.79, 95% CI=0.65-0.95, respectively). Although there were some additional suggestive findings (e.g., for oropharyngeal cancer and leukemia), multivitamin use was not associated with the risk of cancer of the breast, prostate, or lung. In this study that comprehensively evaluated multivitamin use in relation to the risk of overall and site-specific malignancies in both men and women, we found little evidence to support beneficial associations, with the exception of colon cancer risk in both sexes.
Citation Format: Jungeun Lim, Stephanie J. Weinstein, Linda M. Liao, Jiaqi Huang, Demetrius Albanes. Multivitamin use and risk of overall and site-specific cancer in the National Institutes of Health - AARP Diet and Health Study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 850.
Abstract 855: Is shift-work associated with increased risk of gastric cancer? A meta-analysis
Authors: Sun Chenyu , Cheng Ce , Bhan Chandur , Ahmed Mubashir Ayaz , Bheesham Nimararta , Lising Jannell F. 
Published: July 2021

Abstract
Introduction: Gastric cancer remains one of the most common cancers worldwide. Shift-work involving circadian disruption was designated as a probable cause of cancer by The International Agency for Research on Cancer. Several studies have investigated the impact of shift work on gastric cancer, however, most of them are with small sample size. Thus, this meta-analysis was conducted.
Method: A comprehensive literature search on PubMed was conducted to identify all relevant studies published prior to September 2020 according to the established inclusion criteria. The quality assessment was performed by the Newcastle-Ottawa Scale (NOS). The pooled relative risk (RR) and 95% confidence intervals (CI) were calculated to estimate the association between the shift-work and gastric cancer risk. A random-effect or fixed-effect model was used to calculate the pooled RR, based on heterogeneity significance. Subgroup analysis was performed based on rotating-shift versus permanent-shift. Sensitivity analysis and publication bias detection were also performed. All statistical analyses were performed using RevMan software (version 5.3; Cochrane library) and STATA 12.0 statistical software (Stata Corp., College Station, TX), and all P values were two-tailed, the test level was 0.05.
Result: 51 articles were obtained from the database search, and 7 articles obtained from other sources. 4 articles involving 36,574 participants were included. All studies were considered moderate to high quality. A non-statistically significant association between shift-work and increased gastric cancer risk was found (RR 1.15, 95%CI: 0.95, 1.37, P=0.14, I2=0%). In the subgroup analysis, neither rotating-shift (RR 1.24, 95%CI: 0.92, 1.67, P=0.16, I2=0%) nor permanent-shift (RR 1.13, 95%CI: 1.10, 0.90, P=0.12, I2=0%) were found to be associated with an increased risk of gastric cancer. Sensitivity analysis by changing fixed-effect models to random-effect models and by omitting each study at a time confirmed the stability of the result. Funnel plot, Egger's test (t=0.70, P=0.554), and Begg's test (z=0.68, P=0.497) found no publication bias of analysis.
Conclusion: The current meta-analysis demonstrates that shift-work is not associated with increased gastric cancer risk. However, only four studies were included. More original studies are needed to further explore shift-work impacts on gastric cancer risk.
Citation Format: Chenyu Sun, Ce Cheng, Chandur Bhan, Mubashir Ayaz Ahmed, Nimararta Bheesham, Jannell F. Lising. Is shift-work associated with increased risk of gastric cancer? A meta-analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 855.
Abstract 883: Parsimonious model to predict length of stay following cystectomy
Authors: Pathak Rashmi , Perez-Morales Jaileene , Patel Sephalie Y. , Poch Michael A. , Schabath Matthew B. 
Published: July 2021

Abstract
BACKGROUND: The gold standard treatment for urinary bladder cancer is cystectomy, which can result in postoperative complications, patient morbidities, and lengthy hospital visits post-surgery. At present, there are limited models that can predict length of stay for patients post cystectomy. Identifying risk factors associated with increased length of stay could have translational implications in mitigating such risk factors. As such, the goal of this study was to generate parsimonious models to predict length of hospital stay (LOHS) following cystectomy in bladder cancer patients.
METHODS: Data from the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) was used to analyze patients who underwent cystectomy between 2014 and 2016. Modeling building approaches were used to identify the most informative preoperative and postoperative covariates to predict LOHS. Separate models were identified for preoperative covariates and for postoperative covariates and the most informative pre- and postoperative covariates were combined into a single model.
RESULTS: This analysis includes 6,074 patients (mean LOHS = 9.4 days). The preoperative (5 covariates; R squared= 0.245 and Adj R-squared = 0.240) and postoperative models (13 covariates; R squared= 0.237 and Adj R-squared = 0.236) were significantly better predictors compared to the ACS risk calculator model (19 covariates; R-square= 0.026 and Adj R-squared = 0.025). Likewise, the combined model (15 covariates) was a significantly better predictor (R squared= 0.241 & Adj R-squared = 0.239) when compared to the ACS risk calculator model. The combined model was subjected into CART analysis to stratify patients into five risk-groups based on ventilator over 48 hours, organ/space surgical site infection, wound disruption, and pneumonia. Patients in the high-risk group had significantly longer mean LOHS of 26.29 days compared to low-risk group of 8.4 days.
CONCLUSIONS: This study identified and validated a clinically important combined model that is to the ACS NSQIP surgical risk calculator to predict LOHS in patients who underwent cystectomy. Patients at high-risk may benefit from allocation of additional follow-up to prevent longer LOHS.
Citation Format: Rashmi Pathak, Jaileene Perez-Morales, Sephalie Y. Patel, Michael A. Poch, Matthew B. Schabath. Parsimonious model to predict length of stay following cystectomy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 883.
Abstract 885: A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO
Authors: Blackford Amanda L. , Childs Erica J. , Porter Nancy , Petersen Gloria , Rabe Kari , Gallinger Steven , Borgida Ayelet , Syngal Sapna , Schwartz Ann , Cote Michele , Hruban Ralph , Goggins Michael , Klein Alison P. , Parmigiani Giovanni 
Published: July 2021

Abstract
Introduction: Identifying families with an underlying inherited cancer predisposition is a major goal of cancer prevention efforts. Mendelian risk models have been developed to better predict the risk associated with a pathogenic variant of developing breast/ovarian cancer (with BRCAPRO), and the risk of developing pancreatic cancer (PANCPRO). Given that pathogenic variants involving BRCA2 and BRCA1 predispose to all three of these cancers, we developed a joint risk model to capture shared susceptibility.
Methods: We expanded the existing framework for PANCPRO and BRCAPRO to model underlying risk of pancreatic, breast, and ovarian cancer. We then validated this model on three datasets each reflecting the target populations for these models, including patients referred to a high-risk genetics clinic, patients with multiple family members with pancreatic cancer who underwent genetic testing for BRCA1/2, as well as a prospective registry of pancreatic cancer families. The new model is designated BRCAPANCPRO.
Results: BRCAPANCPRO yielded good discrimination for differentiating BRCA1 and BRCA2 carriers from non-carriers (AUC = 0.84, 95% CI: 0.78, 0.87) and was reasonably well-calibrated for predicting future risk of pancreatic cancer (observed-to-expected (O/E) ratio = 0.82 [0.69, 0.94]). In these families, BRCAPANCPRO outperformed both the prior BRCAPRO and PANCPRO models.
Discussion: The BRCAPANCPRO model improves the identification of families with a pathogenic variant in BRCA2 or BRCA1, particularly for families where there is the co-occurrence of pancreatic cancer in addition to breast and/or ovarian cancer. The model also improves the prediction of pancreatic cancer among families with a pancreatic cancer family history, with or without breast and/or ovarian cancer.
Citation Format: Amanda L. Blackford, Erica J. Childs, Nancy Porter, Gloria Petersen, Kari Rabe, Steven Gallinger, Ayelet Borgida, Sapna Syngal, Ann Schwartz, Michele Cote, Ralph Hruban, Michael Goggins, Alison P. Klein, Giovanni Parmigiani. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 885.
Abstract 895: Multi-trajectory models of multiple myeloma progression among patients with monoclonal gammopathy of undetermined significance
Authors: Avila Maira A. Castaneda , Lapane Kate L. , Pearson Sharina , Gurwitz Jerry , Zhou Yanhua , Epstein Mara 
Published: July 2021

Abstract
Background: Understanding the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma is needed to identify patients who would benefit from closer clinical surveillance. Given that two of the defining criteria of multiple myeloma are renal failure and anemia, we described the trajectories of creatinine and hemoglobin over time in patients with a diagnosis of MGUS.
Methods: We analyzed data from 429 patients who were diagnosed with MGUS at a large provider group in central Massachusetts between 2007 and 2015 and were followed up through 2018. Patients diagnosed with MGUS were identified by a previously validated case-finding algorithm using health claims and electronic health record data. Group-based trajectory modeling was used to identify groups of patients with distinct laboratory value trajectories of creatinine (mg/dL) and hemoglobin (mg/dL).
Results: The study sample was mostly non-Hispanic white (85.1%) with a mean age of 75 years at MGUS diagnosis. Three multi-trajectory groups were identified. Patients in Group 1 (54.3%) and Group 2 (43.1%) had increasing serum levels of creatinine and decreasing levels of hemoglobin over time, with group 2 having higher increments. Group 3 (2.6%) patients had increasing levels of creatinine and stable low levels of hemoglobin. Patients with MGUS in group 2 were older, less likely to have a prior cancer diagnosis, and had fewer comorbidities than other groups. Twenty-one patients (4.9%) developed multiple myeloma during the study period, with incidence proportions of 0.5%, 1.5%, and 1.6%, respectively for patients in groups 1, 2, and 3.
Conclusion: The data suggest that certain subpopulations of patients with MGUS can be characterized by biomarker trajectories over time. Future research should further investigate how these trajectories may be related to risk of progression to multiple myeloma.
Citation Format: Maira A. Castaneda Avila, Kate L. Lapane, Sharina Pearson, Jerry Gurwitz, Yanhua Zhou, Mara Epstein. Multi-trajectory models of multiple myeloma progression among patients with monoclonal gammopathy of undetermined significance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 895.
Abstract 90: Fatty acid synthesis is required for breast cancer brain metastasis
Authors: Ferraro Gino B. , Ali Ahmed , Luengo Alba , Kodack David P. , Deik Amy , Abbott Keene L. , Bezwada Divya , Blanc Landry , Prideaux Brendan , Jin Xin , Possada Jessica M. , Chen Jiang , Chin Christopher R. , Amoozgar Zohreh , Ferreira Raphael , Chen Ivy , Naxerova Kamila , Ng Christopher , Westermark Anna M. , Duquette Mark , Roberge Sylvie , Lyssiotis Costas A. , Duda Dan G. , Golub Todd R. , Davidson Shawn M. , Fukumura Dai , Dartois Véronique A. , Clish Clary B. , Heiden Matthew G. Vander , Jain Rakesh K. 
Published: July 2021

Abstract
Brain metastases are refractory to therapies that otherwise control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the unique brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore metabolic adaptations required for breast cancer growth in the brain microenvironment may also introduce liabilities that can be exploited for therapy. Here, we assessed how metabolism differs between breast tumors growing in the brain versus extracranial sites and found that fatty acid synthesis is elevated in breast tumors growing in the brain. We determine that this phenotype is an adaptation to decreased lipid availability in the brain relative to other tissues, which results in a site-specific dependency on fatty acid synthesis for breast tumors growing at this site. Genetic or pharmacological inhibition of fatty acid synthase (FASN) reduces HER2+ breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies.
Citation Format: Gino B. Ferraro, Ahmed Ali, Alba Luengo, David P. Kodack, Amy Deik, Keene L. Abbott, Divya Bezwada, Landry Blanc, Brendan Prideaux, Xin Jin, Jessica M. Possada, Jiang Chen, Christopher R. Chin, Zohreh Amoozgar, Raphael Ferreira, Ivy Chen, Kamila Naxerova, Christopher Ng, Anna M. Westermark, Mark Duquette, Sylvie Roberge, Costas A. Lyssiotis, Dan G. Duda, Todd R. Golub, Shawn M. Davidson, Dai Fukumura, Véronique A. Dartois, Clary B. Clish, Matthew G. Vander Heiden, Rakesh K. Jain. Fatty acid synthesis is required for breast cancer brain metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 90.
Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer
Authors: Fessler Shawn P. , Wang Jason , Collins Scott D. , Qin LiuLiang , Avocetien Kenneth , Xu Ling , Eydelloth Ronald , Vonderfecht Steven , Chin Chen-Ni , Bradley Steven , Clardy Susan , Dirksen Anouk , Ditty Elizabeth , Du Bingfan , Kim Dokyong , Mosher Rebecca , Ter-Ovanesyen Elena , Slocum Kelly , Uttard Alex , Wongthida Phonphimon , Zurita Jeffrey , Toader Dorin , Damelin Marc , Lowinger Timothy B. 
Published: July 2021

Abstract
XMT-1660 is a novel Dolasynthen-based antibody drug conjugate carrying a DolaLock payload with controlled bystander effect and targeting B7-H4, a tumor antigen that is broadly expressed on the cell surface in breast, ovarian and endometrial cancers. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. XMT-1660 is comprised of an anti-B7-H4 antibody site-specifically conjugated to Dolasynthen, with a total of 6 DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads per antibody (DAR-6).
To select the optimal ADC, three ADCs using the same antibody and DolaLock payload were compared: site-specific Dolasynthen-based DAR-2 and DAR-6 ADCs, and a stochastically conjugated Dolaflexin-based DAR-12 ADC. In vitro, no significant differences were observed among the 3 ADCs: all exhibited specific recognition of B7-H4 and elicited potent cytotoxicity against B7-H4-expressing cancer cells. In vivo, XMT-1660 consistently exhibited more anti-tumor activity than the other ADCs in TNBC models and ER+/HER2- models after single, equivalent doses based on payload. XMT-1660 demonstrated dose-dependent anti-tumor activity and induced sustained tumor regressions after a single administration. XMT-1660 and the Dolasynthen DAR-2 ADC both exhibited improved pharmacokinetics in mouse relative to the Dolaflexin DAR 12 ADC.
These data indicate that XMT-1660 exhibited a superior preclinical profile to the other ADCs and more generally demonstrate the importance of DAR-ranging studies to identify the optimal antibody-drug conjugate for a given target. These results, as well as results from exploratory toxicology studies in non-human primates, strongly support the clinical development of XMT-1660.
Citation Format: Shawn P. Fessler, Jason Wang, Scott D. Collins, LiuLiang Qin, Kenneth Avocetien, Ling Xu, Ronald Eydelloth, Steven Vonderfecht, Chen-Ni Chin, Steven Bradley, Susan Clardy, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Dokyong Kim, Rebecca Mosher, Elena Ter-Ovanesyen, Kelly Slocum, Alex Uttard, Phonphimon Wongthida, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger. XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 907.